CBFP
ANIX icon

Cedar Brook Financial Partners’s Anixa Biosciences ANIX Stock Holding History

Cedar Brook Financial Partners’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$30K – 380
2021
Q4 		$30K Hold
10,000
– – 0.01% 379
2021
Q3 		$48K Buy
+10,000
New +$45.1K 0.01% 345

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Cedar Brook Financial Partners's ANIX Position: Q1 2022 in Review

Cedar Brook Financial Partners sold out of Anixa Biosciences (ANIX) in Q1 2022, closing a stake of 10,000 shares — an estimated $30K sold.

Cedar Brook Financial Partners first reported a position in ANIX in Q3 2021 and held it in 2 quarters. The position peaked at $48K in Q3 2021. 41 funds tracked by Wall St. Rank hold ANIX as of Q1 2022.

  • Cedar Brook Financial Partners reported no remaining Anixa Biosciences position as of Q1 2022 after selling out during the quarter.
  • Cedar Brook Financial Partners sold 10,000 Anixa Biosciences shares in Q1 2022, an estimated $30K.
  • Cedar Brook Financial Partners first reported a position in Anixa Biosciences in Q3 2021 and held it in 2 quarters.
  • Cedar Brook Financial Partners's Anixa Biosciences position peaked at $48K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2022.

Based on Cedar Brook Financial Partners's 13F filing for Q1 2022, filed 6 Apr 2022.